Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
Neumora Therapeutics has initiated a Phase 1 clinical study of NMRA-898, a second-generation M4 muscarinic receptor positive allosteric modulator (PAM) that originated from research conducted in collaboration with the Warren Center for Neuroscience Drug Discovery (WCNDD).
This first-in-human study evaluates the safety, tolerability, and pharmacokinetics of NMRA-898 in healthy participants.
The program reflects ongoing efforts to translate fundamental discoveries in muscarinic receptor biology into potential therapeutic applications for neuropsychiatric disorders.
Read the full announcement from Neumora Therapeutics ➡️ https://lnkd.in/ec8VKqVP